EDT, during which managementwill make a brief presentation focusing on the company’s results, strategies andoperating trends. Interested parties can listen to the conference call and viewaccompanying slides via webcast at The webcast will be availablefor replay following the call. Those wishing to dial in to the call viatelephone can do so at (877) 941-2332 or (480) 629-9722. About AECOMAECOM (NYSE:ACM) is a global provider of professional technical and managementsupport services to a broad range of markets, including transportation,facilities, environmental and energy. With 43,000 employees around the world,AECOM is a leader in all of the key markets that it serves. AECOM provides ablend of global reach, local knowledge, innovation, and technical excellence indelivering solutions that enhance and sustain the world’s built, natural, andsocial environments.

A Fortune 500 company, AECOM serves clients in more than100 countries and had revenue of $5.9 billion during the 12-month period endedMarch 31, 2009. More information on AECOM and its services can be found at. Forward-Looking Statements: All statements in this press release other thanstatements of historical fact are “forward-looking statements” for purposes offederal and state securities laws, including any projections of earnings orother financial items; any statements of the plans, strategies and objectivesfor future operations; and any statements regarding future economic conditionsor performance. Although we believe that the expectations reflected in ourforward-looking statements are reasonable, actual results could differmaterially from those projected or assumed in any of our forward-lookingstatements.

Important factors that could cause our actual results, performanceand achievements, or industry results to differ materially from estimates orprojections contained in forward-looking statements include: uncertaintiesrelated to funding, audits, modifications and termination of long-termgovernment contracts; losses under fixed-price contracts; limited control overoperations run through our joint venture entities; misconduct by our employeesor consultants or our failure to comply with laws or regulations; failure tosuccessfully execute our acquisition strategy; the need to retain and recruitkey technical and management personnel; and unexpected adjustments andcancellations related to our backlog. Additional factors that could cause actualresults to differ materially from our forward-looking statements are set forthin our reports filed with the Securities and Exchange Commission. We do notintend, and undertake no obligation, to update any forward-looking statement. WOBURN, Mass.–(Business Wire)–ArQule, Inc.

(NASDAQ: ARQL) today announced its financial results for the firstquarter of 2009. For the quarter ended March 31, 2009, the Company reported a net loss of$9,908,000 or $0.23 per share, compared to a net loss of $13,914,000, or $0.32per share, for the first quarter of 2008. At March 31, 2009, the Company had a total of $192,371,000 in cash, equivalentsand marketable securities, which includes $47,750,000 drawn down during thethird and fourth quarters of 2008 under notes payable that are collateralized bythe Company`s auction rate securities. Net of these notes, at March 31, 2009 theCompany had a total of $144,621,000. Operational Highlights* ARQ 197, a selective inhibitor of c-Met receptor tyrosine kinase* Patient enrollment in the Phase 2 MiT (Microphthalmia Transcription Factor)and NSCLC (non-small cell lung cancer) trials proceeding as planned * Dosing of the first patients in a Phase 1 trial in HCC (hepatocellularcarcinoma) and in a new combination therapy arm with ARQ 197 and gemcitabine inpancreatic cancer* ARQ 621, a novel inhibitor of the Eg5 kinesin motor protein* Completed accrual of the first patient cohort in a Phase 1 safety and dosefinding trial”In partnership with Daiichi Sankyo, we continue to expand the developmentprogram for ARQ 197,” said Paolo Pucci, chief executive officer of ArQule. “Eachof the four tumor programs currently in development is based upon the biologicalrationales for c-Met inhibition in the respective tumor types. Specifically inour newest program, HCC, the over-expression of c-Met and its ligand, hepatocytegrowth factor, is associated with poor patient prognosis.